Impact of Ibis on Patients With Advanced COPD
Not Applicable
- Conditions
- COPD
- Registration Number
- NCT03131622
- Lead Sponsor
- Senscio Systems
- Brief Summary
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
- Gold Stage II with a CAT Score above 19
- Gold Stage III/IV with a CAT Score above 14
Exclusion Criteria
- Cognitive or physical impediments that inhibits patients from interacting with our digital therapeutics platform.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Reduction in Acute Care Utilization 6 months and then again at 1 year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Ibis™ digital therapeutics in reducing COPD exacerbations?
How does Ibis™ compare to standard-of-care interventions for acute COPD management in clinical trials?
Are there specific biomarkers associated with improved outcomes in COPD patients using Ibis™?
What adverse events are reported with Ibis™ digital health solutions in advanced COPD populations?
What are the potential synergies of combining Ibis™ with bronchodilators or inhaled corticosteroids in COPD management?